Citadel Advisors
AAPG

Citadel Advisors’s Ascentage Pharma AAPG Stock Holding History

Citadel Advisors’s Portfolio AAPG Stock Details AAPG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-9,737
Closed -$255K – 14632
2025
Q4 		$255K Buy
9,737
+85
+0.9% +$2.78K ﹤0.01% 10506
2025
Q3 		$383K Buy
+9,652
New +$391K ﹤0.01% 9773

Other funds holding AAPG

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
XC
XY Capital Central, Hong Kong $101M AUM 1.14% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

Citadel Advisors's AAPG Position: Q1 2026 in Review

Citadel Advisors sold out of Ascentage Pharma (AAPG) in Q1 2026, closing a stake of 9,737 shares — an estimated $255K sold.

Citadel Advisors first reported a position in AAPG in Q3 2025 and held it in 2 quarters. The position peaked at $383K in Q3 2025. 7 funds tracked by Wall St. Rank hold AAPG as of Q1 2026.

  • Citadel Advisors reported no remaining Ascentage Pharma position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 9,737 Ascentage Pharma shares in Q1 2026, an estimated $255K.
  • Citadel Advisors first reported a position in Ascentage Pharma in Q3 2025 and held it in 2 quarters.
  • Citadel Advisors's Ascentage Pharma position peaked at $383K in Q3 2025.
  • 7 funds tracked by Wall St. Rank held Ascentage Pharma as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.